The identification of oncogenic driver mutations in lung cancer has led to the rapid rise of genotype-directed target therapy such as EGFR tyrosine kinase inhibitors (TKIs) and has shown dramatic clinical benefits [3]. This evidence concerns the gene EGFR and lung carcinoma.